AntriaBio has announced the private placement of 4.5 million shares of its common stock, priced at $1 a share, to raise $4.5m in gross proceeds.

The US-based clinical-stage biopharmaceutical company plans to use the funds for general corporate purposes.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Australian speciality pharmaceutical company Race Oncology has announced the private placement of 12.5 million shares priced at A$0.2 ($0.16) a share to raise gross proceeds of A$2.5m ($1.78m).

Race Oncology plans to use the funds for the launch of its chemotherapy drug, Bisantrene.

Invenra has formed a partnership with Merck & Co. to engage in the discovery of therapeutic antibodies identified by the latter.

See Also:

The agreement will enable Invenra to utilise the mAbSeq technology to progress its antibody discovery.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"Australian speciality pharmaceutical company Race Oncology has announced the private placement of 12.5 million shares priced at A$0.2 ($0.16) a share to raise gross proceeds of A$2.5m ($1.78m)."

Invenra is an antibody discovery and development company based in the US.

Silk Road Medical, a US-based R&D services provider for neurovascular diseases, has secured $47m in a venture financing round led by Norwest Venture Partners.

The company will use the funds to move its proprietary ENROUTE family of products towards commercialisation stage.

Shenzhen Kangtai Biological Products has announced a public offering of convertible bonds to raise gross proceeds of up to CNY356.6m ($52.65m).

Based in China, Shenzhen Kangtai specialises in the research, development and production of vaccines and other products.